26,071 Shares of Roivant Sciences Ltd. $ROIV Purchased by Englebert Financial Advisers LLC

Englebert Financial Advisers LLC bought a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 26,071 shares of the company’s stock, valued at approximately $953,000. Roivant Sciences accounts for 0.9% of Englebert Financial Advisers LLC’s holdings, making the stock its 25th biggest holding.

Several other institutional investors and hedge funds have also modified their holdings of the business. Assenagon Asset Management S.A. boosted its position in shares of Roivant Sciences by 18.2% in the second quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock worth $295,965,000 after purchasing an additional 1,286,464 shares during the period. Perceptive Advisors LLC lifted its stake in shares of Roivant Sciences by 3.8% during the 1st quarter. Perceptive Advisors LLC now owns 8,285,461 shares of the company’s stock valued at $229,507,000 after buying an additional 300,000 shares in the last quarter. Bank of America Corp DE boosted its holdings in Roivant Sciences by 8.0% in the 1st quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock worth $87,638,000 after buying an additional 235,493 shares during the period. Janus Henderson Group PLC boosted its holdings in Roivant Sciences by 6.1% in the 1st quarter. Janus Henderson Group PLC now owns 3,095,448 shares of the company’s stock worth $85,790,000 after buying an additional 177,339 shares during the period. Finally, Jennison Associates LLC boosted its holdings in Roivant Sciences by 26.7% in the 1st quarter. Jennison Associates LLC now owns 2,982,799 shares of the company’s stock worth $82,624,000 after buying an additional 629,413 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Trading Up 0.6%

Shares of NASDAQ ROIV opened at $34.92 on Wednesday. The firm’s fifty day moving average is $36.58 and its two-hundred day moving average is $33.20. Roivant Sciences Ltd. has a 52-week low of $17.54 and a 52-week high of $42.50.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. The firm had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. On average, research analysts forecast that Roivant Sciences Ltd. will post -2.00 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ROIV shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 24th. Wolfe Research lowered Roivant Sciences from an “outperform” rating to a “peer perform” rating in a research note on Monday, October 12th. TD Cowen upped their price objective on Roivant Sciences from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Stifel Nicolaus began coverage on Roivant Sciences in a research report on Wednesday, September 16th. They set a “buy” rating and a $51.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Roivant Sciences in a research note on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $45.64.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, insider Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $36.25, for a total value of $10,320,628.75. Following the sale, the insider owned 18,630,739 shares of the company’s stock, valued at $675,364,288.75. The trade was a 1.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Melissa B. Epperly sold 17,750 shares of Roivant Sciences stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $36.10, for a total value of $640,775.00. Following the completion of the sale, the director directly owned 14,954 shares in the company, valued at approximately $539,839.40. The trade was a 54.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,622,688 shares of company stock valued at $58,826,636. Insiders own 8.80% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant’s research and development activities have included immunology, dermatology, women’s health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.